OrderlyMeds vs Remedy Meds (2026): prices, structure, verdict

On tirzepatide, OrderlyMeds↗ is cheaper: $299 versus $399 a month all-in — a $100 monthly gap, $1,200 across a year of maintenance dosing.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, OrderlyMeds is cheaper: $149 versus $299 a month all-in — a $150 monthly gap, $1,800 across a year of maintenance dosing.

§ Side by side

§ Each record, read aloud

The two records, condensed

OrderlyMeds: the record, condensed

On tirzepatide, the number that matters at OrderlyMeds is $299 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

There is no membership line. $299 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

To place the number: #8 of 17 verified programs, with the floor $84/month below at NexLife↗ ($215); the approved-product yardstick (Zepbound (LillyDirect↗)) sits at $449, so the compounded case here is worth $150 a month. A year at this figure: $3,588 monthly-billed.

Start with the load-bearing figure: $149 a month, all-in, is what OrderlyMeds charges for semaglutide at the 2.4 mg basis. It is a flat structure: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

There is no membership line. $149 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #4 of 20 in the verified semaglutide index — $16/month above the floor (Oak Longevity, $133) — and sits $200 under the brand benchmark (Wegovy (NovoCare↗), $349 at maintenance). Annualized, a monthly-billed year here runs $1,788.

Operationally at OrderlyMeds: shipping included; commitment none stated; cancellation not published; pharmacy not publicly named — ask in writing before paying; states: not published; evidence no public price, captured 2026-08-05. The full record with source and archive links: the OrderlyMeds page · visit OrderlyMeds ↗

Remedy Meds: the record, condensed

Start with the load-bearing figure: $399 a month, all-in, is what Remedy Meds charges for tirzepatide at the 10 mg basis. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $399 is the whole subscription, which makes Remedy Meds unusually easy to compare and unusually easy to leave.

To place the number: #15 of 17 verified programs, with the floor $184/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $50 a month. A year at this figure: $4,788 monthly-billed.

Remedy Meds’s semaglutide program bills $299 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. The price is dose-flat: the standard titration ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

There is no membership line. $299 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #19 of 20 in the verified semaglutide index — $166/month above the floor (Oak Longevity, $133) — and sits $50 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $3,588.

Operationally at Remedy Meds: shipping included; commitment unknown; cancellation not published; pharmacy not publicly named — ask in writing before paying; states: not published; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Remedy Meds page · visit Remedy Meds ↗

Tirzepatide: the duel in full

Put the two tirzepatide figures side by side and hold them there: OrderlyMeds at $299, Remedy Meds at $399 — a $100 monthly spread that compounds to $1,200 over a maintenance year and $2,400 over two.

Both figures are dose-flat, which is the cleanest possible comparison: two ceilings, no titration surprises on either side, and the $100 gap is exactly what it appears to be.

Semaglutide: the duel in full

The semaglutide arithmetic between these two is short: $149 (OrderlyMeds) against $299 (Remedy Meds). $150 a month sounds survivable; $1,800 a year is a decision.

Both figures are dose-flat, which is the cleanest possible comparison: two ceilings, no titration surprises on either side, and the $150 gap is exactly what it appears to be.

A way to feel the $100 monthly gap: over a year it funds 4.0 extra months at OrderlyMeds’s own rate — the difference is not decoration, it is medication. Over two years it compounds to $2,400, which is the horizon at which structural details (prepaid ladders, membership drag, dose-tier repricing) start mattering more than the sticker itself.

Run the same two programs on the committed basis: OrderlyMeds $299/mo month-to-month against Remedy Meds $399/mo month-to-month. The order holds: OrderlyMeds leads on both readings, so plan structure sharpens the verdict here rather than reversing it. Whichever basis fits your commitment level, the upfront totals above are the honest units.

§ The clock, run forward

Three, six, twelve, twenty-four months — best path each way

3 months: OrderlyMeds $897 monthly; Remedy Meds $1,197 monthly — best path favors OrderlyMeds by $300. 6 months: OrderlyMeds $1,794 monthly; Remedy Meds $2,394 monthly — best path favors OrderlyMeds by $600. 12 months: OrderlyMeds $3,588 monthly; Remedy Meds $4,788 monthly — best path favors OrderlyMeds by $1,200. 24 months: OrderlyMeds $7,176 monthly; Remedy Meds $9,576 monthly — best path favors OrderlyMeds by $2,400.

Prepaid paths above are billed upfront and assume the published rate holds (the 24-month figures extend the 12-month rate, an assumption worth naming). The honest reading: over short horizons the monthly gap decides; over long horizons the prepaid ladders and structural traps (dose tiers, memberships) take over — which is exactly the split the verdict section below scores.

The same clock, on semaglutide

3 mo: OrderlyMeds $447 vs Remedy Meds $897 — $450 to OrderlyMeds. 6 mo: OrderlyMeds $894 vs Remedy Meds $1,794 — $900 to OrderlyMeds. 12 mo: OrderlyMeds $1,788 vs Remedy Meds $3,588 — $1,800 to OrderlyMeds. 24 mo: OrderlyMeds $3,576 vs Remedy Meds $7,176 — $3,600 to OrderlyMeds.

Same rules as above: prepaid figures are upfront commitments, and the 24-month lines extend the 12-month rate as a stated assumption. Where the two molecules crown different winners between these two programs, that split is itself the finding — molecule choice and provider choice are separate decisions.

§ Structure vs structure

Everything besides the price

Coverage: OrderlyMeds publishes “not published”; Remedy Meds publishes “not published” — for anything short of an explicit 50-state claim, intake is the final word.

Neither names its pharmacy publicly — the single most useful disclosure in this category, missing on both sides; ask each, in writing, before paying either.

Exit terms: OrderlyMeds — none stated; not published. Remedy Meds — unknown; not published.

Evidence: OrderlyMeds no public price (captured 2026-08-05); Remedy Meds third-party reported (2026-08-05). Where a figure is stated-not-verified, weight it accordingly — it is a claim we could not capture on the company’s own pages.

The pattern worth internalizing: in this market, structural honesty and price honesty travel together. Programs that publish pharmacies and state lists tend to publish real maintenance prices; programs that hide one usually hide the other.

In the full tirzepatide index these two sit at #8 and #15 of 17: between them lie 6 other programs, and the whole ladder is at cheapest tirzepatide providers. In the full semaglutide index these two sit at #4 and #19 of 20: between them lie 14 other programs, and the whole ladder is at cheapest semaglutide providers.

§ If you move

Switching between OrderlyMeds and Remedy Meds

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (OrderlyMeds: not published; Remedy Meds: not published) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings